{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:39:20Z","timestamp":1789612760138,"version":"build-2803163510"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Burns"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.burns.2021.11.004","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T20:49:13Z","timestamp":1637182153000},"page":"263-280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Impact of multiple medical interventions on mortality, length of hospital stay and reepithelialization time in Toxic Epidermal Necrolysis, Steven-Johnsons Syndrome, and TEN\/SJS Overlap \u2013 Metanalysis and metaregression of observational studies"],"prefix":"10.1016","volume":"48","author":[{"given":"A.","family":"Krajewski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Maciejewska-Markiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Jakubczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Markowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Stru\u017cyna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"M\u0105dry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mazurek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Skonieczna-\u017bydecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.burns.2021.11.004_bib1","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/j.bjps.2016.01.034","article-title":"UK guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis in adults 2016","volume":"69","author":"Creamer","year":"2016","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"10.1016\/j.burns.2021.11.004_bib2","article-title":"British Association of Dermatologists guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis in children and young people","volume":"2019","author":"McPherson","year":"2018","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.burns.2021.11.004_bib3","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jaad.2014.04.044","article-title":"Etanercept therapy for toxic epidermal necrolysis","volume":"71","author":"Paradisi","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.burns.2021.11.004_bib4","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.jid.2018.04.027","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis: a multicenter retrospective study of 377 adult patients from the United States","volume":"138","author":"Micheletti","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.burns.2021.11.004_bib5","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.burns.2017.09.015","article-title":"Improving mortality outcomes of Stevens Johnson syndrome\/toxic epidermal necrolysis: A regional burns centre experience","volume":"44","author":"Nizamoglu","year":"2018","journal-title":"Burns"},{"key":"10.1016\/j.burns.2021.11.004_bib6","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/jamadermatol.2016.5668","article-title":"Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"153","author":"Zimmermann","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.burns.2021.11.004_bib7","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.16137","article-title":"Systemic therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: a SCORTEN-based systematic review and meta-analysis","author":"Torres-Navarro","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.burns.2021.11.004_bib8","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ."},{"key":"10.1016\/j.burns.2021.11.004_bib9","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ."},{"key":"10.1016\/j.burns.2021.11.004_bib10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.burns.2021.11.004_bib11","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ."},{"key":"10.1016\/j.burns.2021.11.004_bib12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics."},{"key":"10.1016\/j.burns.2021.11.004_bib13","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005373-200003000-00017","article-title":"Treatment of toxic epidermal necrolysis with cyclosporin A","volume":"48","author":"Arevalo","year":"2000","journal-title":"J Trauma"},{"key":"10.1016\/j.burns.2021.11.004_bib14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archderm.139.1.33","article-title":"Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression","volume":"139","author":"Bachot","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.burns.2021.11.004_bib15","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1172\/JCI93349","article-title":"Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions","volume":"128","author":"Wang","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.burns.2021.11.004_bib16","first-page":"24","article-title":"The use of cyclosporine for Stevens-Johnson syndrome-toxic epidermal necrolysis spectrum at the University of Louisville: a case series and literature review","author":"Conner","year":"2018","journal-title":"Dermatol Online J."},{"key":"10.1016\/j.burns.2021.11.004_bib17","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1016\/j.jid.2017.05.022","article-title":"Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches","volume":"137","author":"Gonzalez-Herrada","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.burns.2021.11.004_bib18","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2016.07.048","article-title":"Cyclosporine treatment for Stevens-Johnson syndrome\/toxic epidermal necrolysis: Retrospective analysis of a cohort treated in a specialized referral center","volume":"76","author":"Lee","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.burns.2021.11.004_bib19","doi-asserted-by":"crossref","first-page":"312","DOI":"10.4103\/ijdvl.IJDVL_201_16","article-title":"Effectiveness, safety and tolerability of cyclosporine versus supportive treatment in Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis: a record-based study","volume":"83","author":"Mohanty","year":"2017","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.burns.2021.11.004_bib20","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jid.2017.12.034","article-title":"Cyclosporine for epidermal necrolysis: absence of beneficial effect in a retrospective cohort of 174 patients-exposed\/unexposed and propensity score-matched analyses","volume":"138","author":"Poizeau","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.burns.2021.11.004_bib21","doi-asserted-by":"crossref","first-page":"686","DOI":"10.4103\/0378-6323.116738","article-title":"Cyclosporine in Stevens Johnson syndrome and toxic epidermal necrolysis and retrospective comparison with systemic corticosteroid","volume":"79","author":"Singh","year":"2013","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.burns.2021.11.004_bib22","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1365-2133.2010.09863.x","article-title":"Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"163","author":"Valeyrie-Allanore","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.burns.2021.11.004_bib23","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.burns.2018.12.018","article-title":"Combination therapy: Etanercept and intravenous immunoglobulin for the acute treatment of Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"45","author":"Pham","year":"2019","journal-title":"Burns."},{"key":"10.1016\/j.burns.2021.11.004_bib24","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/ijd.14426","article-title":"A 10-year retrospective cohort study of the management of toxic epidermal necrolysis and Stevens-Johnson syndrome in a New South Wales state referral hospital from 2006 to 2016","volume":"58","author":"Chan","year":"2019","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.burns.2021.11.004_bib25","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3892\/etm.2015.2549","article-title":"Clinical characteristics and treatment outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"10","author":"Chantaphakul","year":"2015","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.burns.2021.11.004_bib26","doi-asserted-by":"crossref","first-page":"944","DOI":"10.4102\/sajhivmed.v20i1.944","article-title":"Outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in HIV-infected patients when using systemic steroids and\/or intravenous immunoglobulins in Pietermaritzburg, South Africa","volume":"20","author":"Chateau","year":"2019","journal-title":"South Afr J HIV Med"},{"key":"10.1016\/j.burns.2021.11.004_bib27","first-page":"743","article-title":"High-dose intravenous immunoglobulins in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese patients: a retrospective study of 82 cases","volume":"20","author":"Chen","year":"2010","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.burns.2021.11.004_bib28","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2500\/108854195778666793","article-title":"The outcome of Stevens-Johnson syndrome treated with corticosteroids","volume":"16","author":"Cheriyan","year":"1995","journal-title":"Allergy Proc"},{"key":"10.1016\/j.burns.2021.11.004_bib29","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/1346-8138.13040","article-title":"Clinical profiles and treatment outcomes of systemic corticosteroids for toxic epidermal necrolysis: a retrospective study","volume":"43","author":"Choonhakarn","year":"2016","journal-title":"J Dermatol"},{"key":"10.1016\/j.burns.2021.11.004_bib30","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4103\/0019-5154.110826","article-title":"A six-month prospective study to find out the treatment outcome, prognosis and offending drugs in toxic epidermal necrolysis from an urban institution in kolkata","volume":"58","author":"Das","year":"2013","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.burns.2021.11.004_bib31","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00000658-198611000-00001","article-title":"Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids","volume":"204","author":"Halebian","year":"1986","journal-title":"Ann Surg"},{"key":"10.1016\/j.burns.2021.11.004_bib32","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/ijd.13379","article-title":"A retrospective analysis of Stevens-Johnson syndrome\/toxic epidermal necrolysis treated with corticosteroids","volume":"55","author":"Liu","year":"2016","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.burns.2021.11.004_bib33","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-4362.1985.tb05857.x","article-title":"Stevens-Johnson syndrome. A review of 34 cases","volume":"24","author":"Ting","year":"1985","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.burns.2021.11.004_bib34","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2500\/108854100778250914","article-title":"Corticosteroid therapy in an additional 13 cases of Stevens-Johnson syndrome: a total series of 67 cases","volume":"21","author":"Tripathi","year":"2000","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.burns.2021.11.004_bib35","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1590\/S0365-05962012000300022","article-title":"Treatment of toxic epidermal necrolysis with intravenous immunoglobulin: a series of three cases","volume":"87","author":"Comparin","year":"2012","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.burns.2021.11.004_bib36","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1111\/ijd.12784","article-title":"Occupational toxic epidermal necrolysis associated with dalbergia cochinchinensis: a retrospective comparative study of eight cases in China","volume":"54","author":"Yang","year":"2015","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.burns.2021.11.004_bib37","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1097\/BCR.0b013e318254d2ec","article-title":"Toxic epidermal necrolysis: performance of SCORTEN and the score-based comparison of the efficacy of corticosteroid therapy and intravenous immunoglobulin combined therapy in China","volume":"33","author":"Zhu","year":"2012","journal-title":"J Burn Care Res"},{"key":"10.1016\/j.burns.2021.11.004_bib38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaad.2007.08.039","article-title":"Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study","volume":"58","author":"Schneck","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.burns.2021.11.004_bib39","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/01.BCR.0000124746.33279.86","article-title":"Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis","volume":"25","author":"Shortt","year":"2004","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.burns.2021.11.004_bib40","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1526-0968.2002.00409.x","article-title":"Plasma exchange in patients with toxic epidermal necrolysis","volume":"6","author":"Bamichas","year":"2002","journal-title":"Ther Apher"},{"key":"10.1016\/j.burns.2021.11.004_bib41","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1001\/archderm.1985.01660120074023","article-title":"Plasmapheresis in severe drug-induced toxic epidermal necrolysis","volume":"121","author":"Kamanabroo","year":"1985","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.burns.2021.11.004_bib42","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/jbcr\/irz073","article-title":"Toxic epidermal necrolysis therapy with TPE and IVIG-10 years of experience of the Burns Treatment Center","volume":"40","author":"Krajewski","year":"2019","journal-title":"J Burn Care Res"},{"key":"10.1016\/j.burns.2021.11.004_bib43","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.bjps.2004.12.007","article-title":"Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report","volume":"58","author":"Lissia","year":"2005","journal-title":"Br J Plast Surg"},{"key":"10.1016\/j.burns.2021.11.004_bib44","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.burns.2017.10.022","article-title":"Treatment of toxic epidermal necrolysis by a multidisciplinary team. A review of literature and treatment results","volume":"44","author":"Papp","year":"2018","journal-title":"Burns"},{"key":"10.1016\/j.burns.2021.11.004_bib45","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.burns.2006.08.014","article-title":"Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis","volume":"33","author":"Stella","year":"2007","journal-title":"Burns"},{"key":"10.1016\/j.burns.2021.11.004_bib46","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jaad.2020.08.122","article-title":"Treating toxic epidermal necrolysis with systemic immunomodulating therapies: A systematic review and network meta-analysis","volume":"84","author":"Tsai","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.burns.2021.11.004_bib47","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1111\/jdv.16137","article-title":"Accuracy of SCORTEN to predict the prognosis of Stevens-Johnson syndrome\/toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"34","author":"Torres-Navarro","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.burns.2021.11.004_bib48","article-title":"Management of toxic epidermal necrolysis with plasmapheresis and cyclosporine a: our 10 years\u2019 experience","volume":"5","author":"Giudice","year":"2017","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"10.1016\/j.burns.2021.11.004_bib49","first-page":"430","article-title":"High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis","volume":"83","author":"Campione","year":"2003","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.burns.2021.11.004_bib50","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jaad.2011.12.014","article-title":"Toxic epidermal necrolysis: five years of treatment experience from a burn unit","volume":"67","author":"Firoz","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.burns.2021.11.004_bib51","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/bjd.12607","article-title":"The role of intravenous immunoglobulin in toxic epidermal necrolysis: a retrospective analysis of 64 patients managed in a specialized centre","volume":"169","author":"Lee","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.burns.2021.11.004_bib52","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1365-2230.2010.03826.x","article-title":"Toxic epidermal necrolysis: retrospective analysis of 21 consecutive cases managed at a tertiary centre","volume":"35","author":"Rajaratnam","year":"2010","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.burns.2021.11.004_bib53","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1080\/09546634.2019.1568380","article-title":"Stevens Johnson syndrome and toxic epidermal necrolysis - an Australian analysis of treatment outcomes and mortality","volume":"30","author":"Tran","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.burns.2021.11.004_bib54","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/archderm.139.1.39","article-title":"Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience","volume":"139","author":"Trent","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.burns.2021.11.004_bib55","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1177\/0885066610390466","article-title":"Serum bicarbonate as a marker to predict mortality in toxic epidermal necrolysis","volume":"26","author":"Yeong","year":"2011","journal-title":"J Intensive Care Med"}],"container-title":["Burns"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305417921003119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305417921003119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T08:16:14Z","timestamp":1759652174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305417921003119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0305417921003119"],"URL":"https:\/\/doi.org\/10.1016\/j.burns.2021.11.004","relation":{},"ISSN":["0305-4179"],"issn-type":[{"value":"0305-4179","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of multiple medical interventions on mortality, length of hospital stay and reepithelialization time in Toxic Epidermal Necrolysis, Steven-Johnsons Syndrome, and TEN\/SJS Overlap \u2013 Metanalysis and metaregression of observational studies","name":"articletitle","label":"Article Title"},{"value":"Burns","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.burns.2021.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd and ISBI. All rights reserved.","name":"copyright","label":"Copyright"}]}}